Business News • PR NewsWire • Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress

Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress

Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress

CAMBRIDGE, Mass., Sept. 16, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a...

View More : https://www.prnewswire.com:443/news-releases/leap-therapeutics-presents-updated-positive-data-from-the-distinguish-study...

Releted News by prnewswire

On-board Charger Market Size Worth $13.96 Billion By 2028 | CAGR: 17.2%: Grand View Research, Inc.

HAI ROBOTICS teams up with Savoye to boost smart warehousing

$ 4.43 Bn growth in Automotive Testing, Inspection, and Certification Market during 2020-2024 | 17,000+ Technavio Research Reports

Oracle and Oxford Nanopore Team Up to Improve Healthcare and Speed Discovery of New Medical Breakthroughs

Medivir invites to a conference call on new clinical data and further studies with MIV-818